Keyword: Bayer

The FDA approved Xarelto for chronic coronary or peripheral artery disease, an indication analysts said is worth $1.5 billion.

Bernstein analysts has recently figured selling animal health is "a real possibility" for Bayer and suggested management to consider it for pharma's sake.

Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.

Bayer is laying off more than 225 workers at its complex in Berkeley, California, as it reorganizes manufacturing of its three hemophilia treatments.

Splitting its drug business from crop and healthcare—or selling off animal health—could be Bayer's “best strategy” for pharma growth.

Bayer’s Americas pharma leader is heading off to biotech, but the German drugmaker has a seasoned veteran ready to step up.

The first dual PI3K-delta/gamma inhibitor will go up against Gilead's Zydelig, the first PI3K inhibitor, and Bayer’s Aliqopa.

After a long court fight, NHS England has prevailed in a fight with two drugmakers over the off-label use of Avastin.

Emgality will likely chase Amgen and Novartis’ first-in-class Aimovig and Teva's Ajovy in the CGRP migraine field.

A Takeda founder descendant blasts the Shire deal, as the company moves its U.S. HQ closer to Shire; Sanofi revamps two global units.